Investors
Oxurion/Investors/News/ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

18 Sep 2017General

Documents

English
Download PDF

Back to news